Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $180M (up 13.1% year over year) with net income of $38M.
Q3 2026 key financials · XBRL
- Revenue
- $180M
- +13.1% YoY · −17.4% QoQ
- Net income
- $38M
- +193.9% YoY · −51.6% QoQ
- Operating margin
- 29.6%
- EPS (diluted)
- $0.18
- +200.0% YoY · −53.8% QoQ
Source: XBRL data from the BIOCRYST PHARMACEUTICALS INC (BCRX) Q3 2026 10-Q on SEC EDGAR. USD.
BIOCRYST PHARMACEUTICALS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $180.3M, up $20.9M YoY from $159.4M
- ORLADEYO revenue $174.8M, up $29.6M YoY excluding European business
- R&D expense $58.2M vs $44.6M, driven by $18.0M navenibart spending
- Liquidity $375.0M; operating cash flow $75.5M, up from $55.4M
- Near-term focus: external innovation, cost containment, ORLADEYO commercialization; specialty-pharmacy inventory benefit in upper teens of millions
Risk Factors
- Newly added regulatory risk: Annora’s January 2026 Paragraph IV notice challenges four ORLADEYO patents expiring May 2040
- Most materially updated strategic risk: Astria acquisition added navenibart execution uncertainty and $400 million Blackstone-funded obligations
- Operational risk: Transition to a new sole-source ORLADEYO specialty pharmacy could disrupt patient shipments and quarterly revenue timing
- Financial risk: Blackstone Term Loans mature January 23, 2031 with quarterly interest tied to SOFR plus 4.50%
- Legal risk: ORLADEYO patent litigation against Annora remains stayed until 2031 with outcome and potential loss currently indeterminable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BIOCRYST PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.